TScan Therapeutics
TCRX
32 hedge funds and large institutions have $73.2M invested in TScan Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 1 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
14% more funds holding
Funds holding: 28 → 32 (+4)
6.94% more ownership
Funds ownership: 58.72% → 65.66% (+6.9%)
5% more capital invested
Capital invested by funds: $69.9M → $73.2M (+$3.32M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$973K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$918K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$446K |
| 4 |
Morgan Stanley
New York
|
+$352K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1M |
| 2 |
Renaissance Technologies
New York
|
-$303K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
26
Aries Wealth Management
Portland,
Maine
| $35.3K | +$23.3K | +10,000 | New |
|
|
WPW
27
Waldron Private Wealth
Bridgeville,
Pennsylvania
| $25.6K | – | – | – |
|
28
Qube Research & Technologies (QRT)
London,
United Kingdom
| $6.17K | +$5.62K | +2,410 | New |
|
29
UBS Group
Zurich,
Switzerland
| $2.85K | +$35 | +15 | +1% |
|
|
ACA
30
Atlas Capital Advisors
Jackson,
Wyoming
| $2.29K | – | – | – |
|
31
Wells Fargo
San Francisco,
California
| $732 | +$481 | +206 | +258% |
|
32
Bank of America
Charlotte,
North Carolina
| $512 | – | – | – |
|
|
MIM
33
Monashee Investment Management
Boston,
Massachusetts
| – | -$1M | -400,000 | Closed |
|
TCRX Hedge Fund Activity: Q3 2023 in Review
32 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2023, worth a combined $73.2M — up 4.7% from $69.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TCRX positions and 1 closed out — a net gain of 5 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $973K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1M sold.
- 32 institutional investors held TScan Therapeutics (TCRX) as of Q3 2023, up from 28 in Q2 2023.
- Funds reported $73.2M of TScan Therapeutics stock for Q3 2023, up 4.7% quarter-over-quarter.
- 6 funds opened new TScan Therapeutics positions in Q3 2023 and 1 closed out, a net change of +5 holders.
- The largest TScan Therapeutics buyer in Q3 2023 was BlackRock, an estimated $973K added.
- The largest TScan Therapeutics seller in Q3 2023 was Monashee Investment Management, an estimated $1M sold.
Based on aggregated 13F filings for Q3 2023.